HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Raja M. Flores Valerie W. Rusch Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flores, R. M. Articles by Rusch, V. W. Search for Related Content PubMed PubMed Citation Articles by Flores, R. M. Articles by Rusch, V. W.

J Thorac Cardiovasc Surg 2006;132:763-768
© 2006 The American Association for Thoracic Surgery

General Thoracic Surgery

Positron emission tomography predicts survival in malignant pleural mesothelioma

^a Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
^b Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York.
^c Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
^d Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.

Presented in part at the 39th American Society of Clinical Oncology meeting, Chicago, Illinois, May 31–June 3, 2003.

Received for publication November 25, 2005; accepted for publication March 21, 2006.

^_* Address for reprints: Raja M. Flores, MD, Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. (Email: floresr{at}mskcc.org).

Objectives: Recent studies suggest that standard uptake value on fluorodeoxyglucose positron emission tomography scan can predict mediastinal lymph node status in malignant pleural mesothelioma. Because mediastinal nodal metastasis is known to be associated with poor prognosis, we hypothesized that standard uptake value on fluorodeoxyglucose positron emission tomography might independently predict survival.

Methods: Patients with pathologically proven mesothelioma underwent fluorodeoxyglucose positron emission tomography scanning. Patients fasted and received a minimum of 10 mCi of F18-fluorodeoxyglucose. Whole-body emission studies were acquired, followed by whole-body transmission scans with iterative reconstruction. On the basis of the maximal chi-square method, a standard uptake value of 10 was chosen to classify patients as low versus high standard uptake value. Survival probabilities for both standard uptake value groups were estimated by the Kaplan-Meier method. A Cox proportional hazards model assessed the joint influence of standard uptake value, histology, and stage on survival.

Results: From 1998 to 2005, 137 patients with malignant pleural mesothelioma underwent positron emission tomography scans. The median follow-up for all surviving patients was 24 months. Median survivals were 9 and 21 months for the high and low standard uptake value groups, respectively (P = .02). In a multivariable analysis, high standard uptake value tumors were associated with a 1.9 times greater risk of death than low standard uptake value tumors (P < .01). Mixed histology carried a 2.9 times greater risk of death than epithelioid histology (P < .01), and stages III and IV had a 1.8 times greater risk of death than stages I and II (P = .05).

Conclusions: Standard uptake value greater than 10, mixed histology, and stages III and IV are poor risk factors in malignant pleural mesothelioma. These findings suggest that fluorodeoxyglucose positron emission tomography can be used to stratify patients for treatment and clinical trials.

This article has been cited by other articles:

				C. Cao, S. K. Krog Andvik, T. D. Yan, C. Kennedy, P. G. Bannon, and B. C. McCaughan Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma - institutional review and current update Interact CardioVasc Thorac Surg, May 1, 2011; 12(5): 754 - 757. [Abstract] [Full Text] [PDF]

				S. Sharif, I. Zahid, T. Routledge, and M. Scarci Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact CardioVasc Thorac Surg, May 1, 2011; 12(5): 806 - 811. [Abstract] [Full Text] [PDF]

				A. Nakas and D. A. Waller Reply to West and Walker Eur J Cardiothorac Surg, May 1, 2011; 39(5): 800 - 801. [Full Text] [PDF]

				T. C. Mineo, V. Ambrogi, M. E. Cufari, and E. Pompeo May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?, Eur J Cardiothorac Surg, September 1, 2010; 38(3): 245 - 252. [Abstract] [Full Text] [PDF]

				A. Nakas, E. Black, J. Entwisle, S. Muller, and D. A. Waller Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage? Eur J Cardiothorac Surg, June 1, 2010; 37(6): 1457 - 1463. [Abstract] [Full Text] [PDF]

				A. K. Nowak, R. J. Francis, M. J. Phillips, M. J. Millward, A. A. van der Schaaf, J. Boucek, A. W. Musk, M. J. McCoy, A. Segal, P. Robins, et al. A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters Clin. Cancer Res., April 15, 2010; 16(8): 2409 - 2417. [Abstract] [Full Text] [PDF]

				T. S. Aukema, J. J. Teunissen, S. A. Burgers, R. van Pel, and W. V. Vogel Extensive Soft-Tissue Metastases From Malignant Pleural Mesothelioma J. Clin. Oncol., July 20, 2009; 27(21): e24 - e25. [Full Text] [PDF]

				T. D. Yan, M. Boyer, M. M. Tin, J. Sim, C. Kennedy, J. McLean, P. G. Bannon, and B. C. McCaughan Prognostic Features of Long-term Survivors After Surgical Management of Malignant Pleural Mesothelioma Ann. Thorac. Surg., May 1, 2009; 87(5): 1552 - 1556. [Abstract] [Full Text] [PDF]

				R. E. BENAMORE, D. R. WARAKAULLE, and Z. C. TRAILL Imaging of pleural disease Imaging, December 1, 2008; 20(4): 236 - 251. [Abstract] [Full Text] [PDF]

				T. C. Mineo, V. Ambrogi, E. Pompeo, A. Baldi, F. Stella, P. Aurea, and M. Marino The Value of Occult Disease in Resection Margin and Lymph Node After Extrapleural Pneumonectomy for Malignant Mesothelioma Ann. Thorac. Surg., May 1, 2008; 85(5): 1740 - 1746. [Abstract] [Full Text] [PDF]

				R. M. Flores, H. I. Pass, V. E. Seshan, J. Dycoco, M. Zakowski, M. Carbone, M. S. Bains, and V. W. Rusch Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 620 - 626. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]

				V. W. Rusch Editorial comment: A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma Eur J Cardiothorac Surg, March 1, 2007; 31(3): 534 - 535. [Full Text] [PDF]